相关实验视频
Updated: Dec 28, 2025

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.1K
2010年至2017年女性参与心血管临床试验
Xurui Jin1, Chanchal Chandramouli2, Brooke Allocco3
1Global Heath Research Center, Duke Kunshan University, China (X.J., E.G., L.L.Y.).
Circulation
|February 18, 2020
概括
在心血管试验中男性仍然占主导地位,但女性的代表性因疾病和试验特征而异. 近年来,中风和心力衰竭试验的参与率有所提高.
科学领域:
- 心血管研究
- 临床试验多样性
- 医疗公平
背景情况:
- 心血管疾病是全球女性死亡的主要原因.
- 妇女在心血管临床试验中的代表性一直很低.
研究的目的:
- 系统评估妇女参与已完成的心血管试验 (2010年至2017年).
- 分析影响女性在心血管疾病研究中的因素.
主要方法:
- 来自ClinicalTrials.gov (2010-2017) 的740项已完成的心血管试验的系统审查.
- 提取疾病类型,赞助商,国家,试验规模,干预和参与者的人口统计数据.
- 计算的女性与男性的比例和因患病率而调整的参与率.
主要成果:
- 总体而言,在862,652名成年参与者中,女性占38. 2%,女性与男性的中位数为0. 51.
- 根据年龄,干预类型,疾病,地区,赞助商和试验规模的代表性有显著差异.
- 参与率对高血压有利,但对冠状动脉疾病和急性冠状动脉综合征较低.
- 在中风和心力衰竭试验中观察到参与率的显著改善 (2013 - 2017年).
结论:
- 尽管总体上男性占主导地位,但女性在心血管试验中的代表性正在改善,特别是在中风和心力衰竭方面.
- 试验特征和疾病类型显著影响女性参与.
- 需要继续努力,以确保在心血管疾病研究中的公平代表性.
相关概念视频
Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
709
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
709
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.9K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
473
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
473
Coronary Artery Disease III: Clinical Manifestations
251
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
251

